Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina. Show more

Location: 419 Davis Drive, Morrisville, NC, 27560, United States | Website: https://www.liquidia.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.204B

52 Wk Range

$8.26 - $19.41

Previous Close

$14.15

Open

$14.12

Volume

1,474,800

Day Range

$13.76 - $14.15

Enterprise Value

1.043B

Cash

169.8M

Avg Qtr Burn

-24.81M

Insider Ownership

13.64%

Institutional Own.

65.04%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.